This is one to keep on the radar, Neurochem Inc (NMRX). Shares of NMRX have been bid up recently as investors anticipate fresh news. Streetinsider.com recently cited an analyst at JEFF as saying, "upcoming action on Kiacta (potentially by end of 2006, with class 1 review) could cause significant volatility in the shares." Results from the first phase 3 study of NRMX's Alzhemed-tramiprosate for the treatment of Alzheimer's disease is expected in the spring of 2007."
Getting my attention is the May options volatility which has surged to 133! Tramiprostate may eventually offer some hope to patients with mild to moderate Alzheimers disease. For now, it's an expensive lottery ticket in the options world, but a development worth watching. The options market has certainlyu taken notice.